Generic placeholder image

当代阿耳茨海默病研究

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Meta-Analysis

阿尔茨海默氏病患者的治疗和护理费用:一项荟萃分析

卷 16, 期 14, 2019

页: [1245 - 1253] 页: 9

弟呕挨: 10.2174/1567205017666200102144640

价格: $65

conference banner
摘要

如今,发达国家已普遍尝试实施战略计划以对抗阿尔茨海默氏病,为此,治疗已成为老龄化社会日益增加的经济负担。目前,对阿尔茨海默氏病(AD)患者的治疗和护理费用尚未得到持续跟踪和记录,因此,经济负担是根据各个国家/地区的记录计算得出的。本文的目的是对由老年精神状态检查(MMSE)确定的疾病阶段相关的老年AD患者的治疗和护理总费用的可用数据进行荟萃分析。使用Web of Science和PubMed数据库进行系统搜索。两名独立的审阅者筛选了确定的记录并选择了2007年至2017年期间发表的相关文章。对与阿尔茨海默氏病的阶段(轻度,中度和重度)相关的三类费用进行了荟萃分析。通过荟萃分析确定的每位患者每年的总费用估算结果为总费用20,461 $。根据MMSE评分表,与疾病阶段相关的总成本为:轻度阶段为14675美元,中度阶段为19975美元,重度阶段为29708美元。荟萃分析证实,成本随着AD的严重性而显着增加。因此,这些发现强调了AD患者,其家庭和医疗保健系统带来的经济负担的严重性,并且在规划未来几年的健康政策策略时必须考虑到这一事实。

关键词: 阿尔茨海默氏病,荟萃分析,费用,小型精神状态检查,发达国家,精神障碍。

Next »
[1]
World Health Organization Mental Health Available from: [cited 2018 March 19].. http://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health/mental-health
[2]
Deb A, Thornton JD, Sambamoorthi U, Innes K. Direct and indirect cost of managing Alzheimer’s disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 17(2): 189-202. (2017)
[http://dx.doi.org/10.1080/14737167.2017.1313118] [PMID: 28351177]
[3]
Amjad H, Wong SK, Roth DL, Huang J, Willink A, Black BS, et al. Health services utilization in older adults with dementia receiving care coordination: the MIND at home trial. Health Serv Res 53(1): 556-79. (2018)
[http://dx.doi.org/10.1111/1475-6773.12647] [PMID: 28083879]
[4]
Michalowsky B, Flessa S, Eichler T, Hertel J, Dreier A, Zwingmann I, et al. Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial. Eur J Health Econ 19(1): 87-102. (2018)
[http://dx.doi.org/10.1007/s10198-017-0869-7] [PMID: 28160100]
[5]
Daras LC, Feng Z, Wiener JM, Kaganova Y. Medicare expenditures associated with hospital and emergency department use among beneficiaries with dementia. Inquiry 54 46958017696757 (2017)
[http://dx.doi.org/10.1177/0046958017696757] [PMID: 28301976]
[6]
Holmerová I, Hort J, Rusina R, Wimo A, Šteffl M. Costs of dementia in the Czech Republic. Eur J Health Econ 18(8): 979-86. (2017)
[http://dx.doi.org/10.1007/s10198-016-0842-x] [PMID: 27785577]
[7]
Butler A, Gallagher D, Gillespie P, Crosby L, Ryan D, Lacey L, et al. Frailty: a costly phenomenon in caring for elders with cognitive impairment. Int J Geriatr Psychiatry 31(2): 161-8. (2016)
[http://dx.doi.org/10.1002/gps.4306] [PMID: 26136186]
[8]
Schaller S, Mauskopf J, Kriza C, Wahlster P, Kolominsky-Rabas PL. The main cost drivers in dementia: a systematic review. Int J Geriatr Psychiatry 30(2): 111-29. (2015)
[http://dx.doi.org/10.1002/gps.4198] [PMID: 25320002]
[10]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7) e1000097 (2009)
[http://dx.doi.org/10.1371/journal.pmed.1000097] [PMID: 19621072]
[11]
Wells G, Shea B, O’Connell J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis (2001) http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAvailable from.: URL. http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp
[12]
Olazarán J, Agüera-Ortiz L, Argimón JM, Reed C, Ciudad A, Andrade P, et al. Costs and quality of life in community-dwelling patients with Alzheimer’s disease in Spain: results from the GERAS II observational study. Int Psychogeriatr 29(12): 2081-93. (2017)
[http://dx.doi.org/10.1017/S1041610217001211] [PMID: 28720158]
[13]
Michalowsky B, Thyriana JR, Eichler T, Hertel J, Wucherer D, Flessa S, et al. Economic analysis of formal care, informal care, and productivity losses in primary care patients who screened positive for dementia in Germany. J Alzheimers Dis 50: 47-59. (2016)
[14]
Wimo A, Reed CC. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer’s disease in three european countries - study design and baseline findings. J Alzheimers Dis 36 (2013) 385-99. (2013)
[15]
Dodel A, Belger M, Reed C, Wimo A, Jones RW, Happich M, et al. Determinants of societal costs in Alzheimer’s disease: GERAS study baseline results. Alzheimers Dement 11(8): 933-45. (2015)
[16]
Gustavssona A, Brinckc P, Bergvall N, Kolasa K, Wimo A, Winblad B, et al. Predictors of costs of care in Alzheimer’s disease: a multinational sample of 1222 patients. Alzheimers Dement 7: 318-27. (2011)
[http://dx.doi.org/10.1016/j.jalz.2010.09.001]
[17]
Rattingera GR, Schwartz S, Mullins CD, Corcoran C, Zuckerman IH, Sanders C, et al. Dementia severity and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement 11: 946-54. (2015)
[http://dx.doi.org/10.1016/j.jalz.2014.11.004]
[18]
Wang G, Chenga Q. Economic impact of dementia in developing countries: an evaluation of alzheimer-type dementia in shanghai, China. J Alzheimer Dise 15: 109-15. (2008)
[19]
Gillespie P, O’Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A. The effects of dependence and function on costs of care for Alzheimer’s disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry 28(3): 256-64. (2013)
[http://dx.doi.org/10.1002/gps.3819] [PMID: 23386588]
[20]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414): 557-60. (2003)
[http://dx.doi.org/10.1136/bmj.327.7414.557] [PMID: 12958120]
[21]
Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2): 193-206. (2006)
[http://dx.doi.org/10.1037/1082-989X.11.2.193] [PMID: 16784338]
[22]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 21(11): 1539-58. (2002)
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[23]
Borenstein M, Hedges L, Rothstein H. Meta-Analysis Fixed effect vs random effects [cited 2018 March 19] Available from. https://www.meta-analysis.com/downloads/M-a_f_e_v_r_e_sv.pdf
[24]
Fang JQ. Medical statistics and computer experiments. New Jersey: World Scientific 2005; p. 948.
[http://dx.doi.org/10.1142/5762]
[25]
Gillespie P, O’Shea E, Cullinan J, Buchanan J, Bobula J, Lacey L, et al. Longitudinal costs of caring for people with Alzheimer’s disease. Int Psychogeriatr 27(5): 847-56. (2015)
[http://dx.doi.org/10.1017/S1041610214002063] [PMID: 25248030]
[26]
Colucci L, Bosco M, Fasanaro AM, Gaeta GL, Ricci G, Amenta F. Alzheimer’s disease costs: what we know and what we should take into account. J Alzheimers Dis 42(4): 1311-24. (2014)
[http://dx.doi.org/10.3233/JAD-131556] [PMID: 25024334]
[27]
Tsolaki M, Papaliagkas V, Frisoni G, Jones R, Touchon J, Spiru L, et al. MCI Patients in Europe: medication and comorbidities. The DESCRIPA Study. Curr Alzheimer Res 13(12): 1407-13. (2016)
[http://dx.doi.org/10.2174/1567205013666160603002704] [PMID: 27335041]
[28]
Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease-a simulation study. Curr Alzheimer Res 10(2): 207-16. (2013)
[http://dx.doi.org/10.2174/1567205011310020011] [PMID: 23036018]
[29]
Yang KC, Chen HH. Probabilistic cost-effectiveness analysis of vaccination for mild or moderate Alzheimer’s disease. Curr Alzheimer Res 13(7): 809-16. (2016)
[http://dx.doi.org/10.2174/1567205013666160129095012] [PMID: 26825097]
[30]
van den Berg B, Brouwer W, van Exel J, Koopmanschap M, van den Bos GA, Rutten F. Economic valuation of informal care: lessons from the application of the opportunity costs and proxy good methods. Soc Sci Med 62(4): 835-45. (2006)
[http://dx.doi.org/10.1016/j.socscimed.2005.06.046] [PMID: 16137814]
[31]
Posnett J, Jan S. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs. Health Econ 5(1): 13-23. (1996)
[http://dx.doi.org/10.1002/(SICI)1099-1050(199601)5:1<13:AID-HEC182>3.0.CO;2-J] [PMID: 8653189]
[32]
Rattinger GB, Schwartz S, Mullins CD, Corcoran C, Zuckerman IH, Sanders C, et al. Dementia severity and the longitudinal costs of informal care in the Cache County population. Alzheimers Dement 11(8): 946-54. (2015)
[http://dx.doi.org/10.1016/j.jalz.2014.11.004] [PMID: 25614127]
[33]
Kiencke P, Daniel D, Grimm C, Rychlik R. Direct costs of Alzheimer’s disease in Germany. Eur J Health Econ 12(6): 533-9. (2011) Epub 2010 Jul 18
[http://dx.doi.org/10.1007/s10198-010-0267-x]
[34]
Leicht H, Heinrich S, Heider D, Bachmann C, Bickel H, van den Bussche H, et al. Net costs of dementia by disease stage. Acta Psychiatr Scand 124(5): 384-95. (2011)
[http://dx.doi.org/10.1111/j.1600-0447.2011.01741.x] [PMID: 21838738]
[35]
Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res 7(4): 358-67. (2010)
[http://dx.doi.org/10.2174/156720510791162430] [PMID: 19939223]
[36]
Mohelska H, Maresova P, Valis M, Kuca K. Alzheimer's disease and its treatment costs: case study in the Czech Republic. Neuropsychiatric Disease and Treatment 11 (2015) 2349-54. (2015)
[37]
Maresova P, Mohelska H, Kuca K. A Social and family load of Alzheimer’s disease. App Eco 48(21): 1936-48. (2016)
[38]
Maresova P, Klimova B, Novotny M, Kuca K. Alzheimer’s and Parkinson’s disease: expected economic impact on Europe - a call for a uniform European strategy. J Alzheimers Dis 54(3): 1123-33. (2016)
[http://dx.doi.org/10.3233/JAD-160484] [PMID: 27567862]
[39]
Wimo A, Jönsson L, Bond J, Prince M, Winblad B. The worldwide economic impact of dementia 2010. Alzheimers Dement 9(1): 1-11.e3. (2013)
[http://dx.doi.org/10.1016/j.jalz.2012.11.006] [PMID: 23305821]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy